Navigation Links
Stem Cell Study Shows Benefits in Treatment of Spinal Injuries
Date:11/10/2010

Stem Cell Study Shows Benefits in Treatment of Spinal Injuries -- SEOUL, South Korea, November 10, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

Stem Cell Study Shows Benefits in Treatment of Spinal Injuries

   

Results of 108 Patients Demonstrate Safety and Efficacy

SEOUL, South Korea, November 10, 2010 /PRNewswire/ -- Dr. Geeta Shroff, founder & medical director of Nutech Mediworld, presented today the summary results of a retrospective clinical study of human embryonic stem cell (hESC) therapy in patients with chronic spinal cord injury (SCI). Speaking at the 2nd Annual World Stem Cells & Regenerative Medicine Congress Asia 2010, Dr. Shroff explained her treatment protocol and clinical results, demonstrating the safety and efficacy of her human embryonic stem cell (hESC) therapy. The groundbreaking study was conducted on 108 chronic SCI patients treated by Dr. Shroff over a 6 year period-2004 to 2009. Dr Geeta Shroff also shared her vision, which is to see hESC therapy available globally as the first line of treatment for many of mankind's worst afflictions and her willingness to collaborate with entities and work with regulatory authorities worldwide, to realise this vision.

About the hESC Technology

Dr. Geeta Shroff has developed a commercially viable technology to isolate hESC, culture them, prepare them for clinical application and store them in ready-to-use form with a shelf life of six months. This technology, which has patents applied for worldwide, provides a safe and effective, 'purely human' product, for the treatment of a wide range of medical conditions. The ready-to-use product is universally acceptable as it does not require any cross- matching and has a shelf life of 6 months, making it amenable to global marketing. The technology is being used clinically to treat many conditions including spinal injuries, multiple sclerosis, Parkinson's disease, diabetes, Lyme disease, cerebral palsy and autism. Since 2002, more than 800 patients from 35 countries have been treated at Nutech Mediworld, New Delhi and the number is steadily growing.

For further information, please contact: Nutech Mediworld info@ntmw.net
'/>"/>

SOURCE Nutech Mediworld
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Study Shows Cardiovascular Deaths in Europe Could Be Prevented
2. Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD
3. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
4. Arizona State University awarded $6.5 million to study nanotechnology and society
5. Molecular Detections Detect-Ready™ MRSA Assay Demonstrates Strong Performance In Independent Comparative Study From Leading UK Hospital
6. Helix BioPharma Completes Definitive GLP Toxicology Studies With L-DOS47 and is Making Final Preparations for its Planned Phase I/II Clinical Study IND/CTA Submissions
7. Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes
8. CoreLab Partners Completes First TQT Study in Japan
9. Kibow Biotech Releases Results of Pilot Scale Study of Its Probiotic Formulation for Kidney Health
10. ISTA Pharmaceuticals Highlights Clinical Data from REMURA™ Phase 2 Study Presented at the 6th International Conference on the Tear Film & Ocular Surface
11. Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... and Azusa, CA (PRWEB) , ... December 07, ... ... of distributed wastewater treatment and resource recovery solutions for industrial facilities, today announced ... , will be the first to use Cambrian’s novel water-energy purchase agreement (WEPA). ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... access program for SmartBiome -- a novel metagenomic deep-sequencing research platform. SmartBiome ... and detection of hundreds of different genes. The selective early access program ...
(Date:12/6/2016)... , Dec. 6, 2016 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... for the fourth quarter and fiscal year ended September 30, 2016. ... , , ... -based life sciences and diagnostics company that develops and commercializes proprietary ... Highlights Achieved revenues of $1.4 million more than ...
(Date:12/6/2016)... ... 06, 2016 , ... Discovering new clues to natural treatments that could allow ... in our brains. And searching for keys to our immune systems by studying parasite-resistant ... the 2017 Edith and Peter O’Donnell Awards by The Academy of ...
Breaking Biology Technology:
(Date:11/29/2016)... 2016 BioDirection, a privately held medical device ... objective detection of concussion and other traumatic brain injury ... a meeting with the U.S. Food and Drug Administration ... Package. During the meeting company representatives reviewed plans for ... to commencement of a planned pilot trial. ...
(Date:11/28/2016)... , Nov. 28, 2016 ... rate of 16.79%" The biometric system market is ... further in the near future. The biometric system market ... in 2022, at a CAGR of 16.79% between 2016 ... integration of biometric technology in smartphones, rising use of ...
(Date:11/22/2016)... 22, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... and Life Sciences Awards as "Most Outstanding in ... unprecedented year of recognition and growth for MedNet, which ... years. iMedNet ™ , MedNet,s ...
Breaking Biology News(10 mins):